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Colorectal cancer is the third most common cancer in both men
and women in the USA, with about 60 new cases a year per
100 000 inhabitants (SEER Cancer Statistics Review, 1997).
Unfortunately, in spite of the advances in the screening and early
diagnosis of these patients (Boyle, 1997), 40–45% are destined to
metastasize and, as a consequence, to receive systemic
chemotherapy. In fact, the combination of 5-fluorouracil (5-FU)
and leucovorin (LV) has been shown to improve survival for a
significant number of advanced colorectal cancer patients
(Machover, 1997). However, the absolute percentage of these
patients who will benefit from the chemotherapy is still low and,
consequently, indications for this approach warrant further discus-
sion (Isacoff and Borud, 1997). Moreover, due to the lack of
predictive factors, the individual response to chemotherapy of
advanced colorectal cancer patients is still difficult to foresee. In
fact, apart from some clinical factors of limited usefulness
(Machiavelli et al, 1991), little is known of the biological and
biochemical markers of colorectal tumour responsiveness to
fluoropyrimidines.
With regard to the mechanism of action, 5-FU is effective
through its active metabolite, FdUMP, which competes with
dUMP for a binding site on the thymidilate synthase (TS) protein,
which is the rate-limiting de novo enzyme for synthesis of thymine
nucleotides necessary for DNA synthesis. In particular, in vitro
evidence suggests that inhibition of TS activity is one of the major
mechanisms for the anti-tumoural effect of 5-FU. Spears et al
demonstrated that sensitivity to 5FU is partly related to its ability
to inhibit TS activity (Spears et al, 1982). In addition, the acute
induction of the TS protein and also the stable amplification of
TS-specific genes seem to be associated with 5-FU resistance
(Johnston et al, 1991). Chu et al suggested that 5-FU resistance is
correlated with increased TS levels after being induced by 5-FU
with post-transcriptional regulation (Chu et al, 1990). Lastly,
Peters et al reported that the LV clinical effect could be related to
the prevention of TS induction after 5-FU administration (Peters et
al, 1994). All these in vitro studies are concordant in suggesting
that 5-FU resistance is effectively related to TS activity in many
tumour cell models.
Apart from the above described biochemical mechanisms, it has
been recently demonstrated that the cytotoxic effects of 5-FU in
some tumour cell lines can be due to apoptosis, the programmed
cell death process regulated by p53-dependent mechanisms but
which also involves other positive and negative molecular control
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factors (Merchant et al, 1996). In particular, Lowe et al reported
that the p53 wild-type expression is required for 5-FU-induced
apoptosis in vitro, and that the acquisition of a p53 mutation
renders the tumour cell unresponsive to drugs (Lowe et al, 1994).
Furthermore, it has also been demonstrated that in a colorectal
cancer cell line bearing an exogeneous wild-type p53 allele, induc-
tion of wild-type p53 greatly potentiates 5-FU cytotoxicity (Yang et
al, 1996). In fact, a p53 function involved in the determination of
clinical response to chemotherapy has been strongly suggested by
the demonstration that p53 modulates the activity of the mdr-1 gene
directly implicated in the regulation of a constitutional multidrug
cell resistance (Chin et al, 1992). Interestingly enough, in colorectal
cancer, a disease generally considered scarcely responsive to
systemic therapy, p53 mutations are very common (Smith et al,
1996) and preliminary data indicate that p53 alterations could
determine clinical tumour resistance (Bulleco et al, 1996).
Recently, stimulating data reported by Lee et al (1997) confirmed
that wild-type p53 can directly modulate the expression of TS,
which is considered the key enzyme for 5-FU cytotoxic activity.
The above considerations and the recent availability of mono-
clonal antibodies for TS detection in formalin-fixed tissue sections
(Johnston et al, 1991) prompted us to verify if TS and p53 primary
tumour expressions evaluated by routine immunohistochemical
assays can be of clinical use for predicting clinical response to
chemotherapy and long-term prognosis in a large series of homo-
geneously-treated advanced colorectal cancer patients.
MATERIALS AND METHODS
Patient characteristics
A consecutive series of 108 patients with advanced colorectal
cancer treated by a first-line 5-FU double modulated
chemotherapy in the Institutions of GOCS-Argentina and for
whom formalin-fixed paraffin-embedded pathological material
was available, were entered in the present retrospective study. A
total of 66/108 patients were enroled in CR-01-83 and CR-06-85
clinical trials, while the remaining 42 were consecutively treated
after the end of above protocols. Clinical results concerning these
protocols have already been published (Machiavelli et al, 1991).
Eligibility criteria for the reported clinical trials included: histo-
logical evidence of colorectal cancer without prior chemotherapy
for metastatic or advanced recurrent (inoperable) disease, age
under 75 years, Eastern Cooperative Oncology Group perfor-
mance status of 0–3 and a life expectancy of at least 10 weeks.
Immediately after diagnosis, the patients received the following
therapeutic schedule: methotrexate (MTX) at 200 mg m–2 intra-
venously (i.v.) by push injection followed after 20 h by 5-FU at
1200 mg m–2 administered as continuous i.v. infusion over 2 h.
Twenty-four hours after MTX administration all patients received
LV at 25 mg i.v. every 6 h for a total of eight doses. Both treatments
were repeated every 15 days until disease progression, severe
toxicity, or death. To be evaluable for response, patients must have
received at least two or more chemotherapy cycles. No radiotherapy
was previously or concomitantly administered to any patient.
Standard UICC criteria were used for evaluation of clinical
response. Clinical objective response included either complete
remission (CR) or partial response (PR) of the disease lasting at
least 3 months. The time-to-progression (TTP) was evaluated from
the initiation of chemotherapy. Overall survival (OS) in the overall
series was computed from start of chemotherapy to death. In
accordance with the guidelines proposed by Simes and Zelen
(1985), total follow-up time from the onset of treatment for
metastatic disease was 103.7 patient years with an average of
11 months (range 1–52) and a failure rate (deaths) of 0.75 failures
per year.
Clinical-pathological characteristics of the 108 patients were as
follows: median age was 59 years (range 23–74); 74/108 (68%)
were males; primary tumour site was colon in 69/108 (24 cases in
right colon) and rectum in 39 cases; 49 patients had advanced
recurrent disease while 59 had metastatic disease at first diagnosis;
lastly, 73 patients had metastatic involvement of the liver. The
histopathological grade according to AJCC modified criteria
(American Joint Committee on Cancer, 1988) permitted the
classification of 26 tumours as well-differentiated (G1), 52 as
moderately or poorly-differentiated (G2), and 30 as undifferenti-
ated (G3) tumours.
Immunohistochemical determination
One formalin-fixed paraffin block of the primary tumour was
selected for each patient, based on the quality of the morphologic
preservation and neoplastic cellularity. Histological sections of
4 microns were cut and destined to specific immunohistochemical
determinations.
The monoclonal antibody (mAb) pAb 1801 used against human
p53, reacts with a denaturation-resistent epitope between amino
acids 32 and 79 and recognizes both wild-type and mutant forms
of the p53 protein.
The mouse monoclonal antibody TS106, kindly provided by PG
Johnston (Navy Medical Oncology Branch, NCI, Bethesda, MD,
USA) was produced in mice infected with a recombinant human
TS protein as already reported (Johnston et al, 1991); this antibody
reacts specifically with human TS and displays a negligible cross-
reactivity with other cellular proteins of human cells.
To detect masked and unmasked antigen sites both for p53 and
TS106, histological sections were deparaffinized and immersed in
a 10 mM citrate buffer (pH 6.0) and exposed to microwaves for a
15 min cycle of 750 W using microwaveable slides. The slides
were then incubated for 1 h in a humidified atmosphere at room
temperature with a 1:400 diluted pAb 1801 monoclonal antibody
(Oncogene Science, Uniondale, NY, USA) or a 1:100 diluted
TS106 monoclonal antibody to detect the presence of p53 or TS
respectively. In the first 20 cases observed, results obtained with
the above technique were compared with those using overnight
incubation at 4°C with the same dilution of monoclonal antibodies
without microwave exposure. We concluded that the sensitivity of
the reaction was enhanced in the microwave slides and therefore
continued the study utilizing this method.
After incubation, the specimens were washed twice with 
phosphate-buffered saline (PBS) solution (pH 7.6) and processed
with the streptavidin–biotin peroxidase method according to the
manufacturer’s recommendations. The slides were then incubated
in aminoethylcarbazol and hydrogen-peroxide chromogen
substrate for 10 min at room temperature, washed in running water
for 2–3 min, counterstained in Mayer’s haematoxylin and
mounted with a permanent medium. The immunoreactivity for
p53 antibody was revealed by a dark brown nuclear staining; in
sporadic areas of a few tumours, a weak cytoplasmic staining was
also observed but not considered in the evaluation of the sample;
the immunoreactivity for TS antibody was revealed by a dark
brown cytoplasm signal in heterogeneous areas of a few tumours.562 A Paradiso et al
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A set of paraffin-embedded colon cancer samples with high
levels of p53 and TS expression were used as positive controls
while negative controls were obtained by omission of the primary
antibody. Tumours cells expressing p53 and TS immunoreactivity
were quantified by two independent observers who evaluated at
least 1000 neoplastic cells in consecutive areas of neoplastic tissue
and numbers of positive cells were then expressed as a percentage
of labelled tumour cells with respect to the total number of tumour
cells evaluated. Subjective scoring was minimized by regarding all
labelled cells as positive irrespective of staining intensity. The
sample evaluation was blind in that the investigators had no
knowledge of the patient’s clinical outcome. Intra- and interlabora-
tory control of p53 immunohistochemical staining and evaluation
has been previously performed (Paradiso et al, 1996).
Statistical analysis
The p53 and TS status were considered dichotomous variables
according to the criteria reported above. Different cut-off values of
positive p53 cells from 0% to 50% with a step-wise increase of 5%
were utilized for analysis of clinical relationships between p53
primary tumour expression and clinical outcome. For TS analysis,
each tumour was classified as positive for any percentage of TS
immunostained cells present within the tumour. The cut-off of
0% of TS-positive cells was retained for analysis of prognostic
relationships.
The association between p53, TS expression and biological or
pathological variables was assessed using the c2 test with the Yates
correction or Fisher’s test. Life-curves were computed by the
Kaplan–Meier product-limit method and compared by log-rank
test. The joint effect of each presumed prognostic variable was
evaluated by a multivariate analysis using the Cox regression
model. In this model, the logarithm of the regression coefficients is
the hazard ratio which is constant in time. The hazards ratios and
their 95% confidence intervals (95% CI) were determined by use
of the putative best prognosis category as reference.
RESULTS
Overall, 24/108 patients responded to polychemotherapy. Median
length of response was 6 months, whereas median overall survival
of the series was 12 months.
p53 expression was evaluable in all 108 cases and was generally
confined to neoplastic tissues while normal clonic mucosa was
only occasionally stained. Overall, p53 was expressed in 53/108
(49%) tumours with 40 (37%) cases having more than 5% of posi-
tive cells. Presence of p53-positive cells (any cut-off value) was
not related to sex, primary tumour site (colon vs rectum; left colon
vs right colon-rectum), initially advanced or recurrent disease,
metastatic site, number of metastases or cytohistological tumour
grade.
TS immunoreactivity was generally of the granular type and
located at the cytoplasmic level of normal and tumour cells (Figure
1). In normal mucosa the staining intensity was much less than that
observed in colorectal tumours and mainly located in the basal
area of the cells. All 108 primary tumours were evaluable for TS
expression, with 54 (50%) cases showing some kind of immuno-
staining and 44 (41%) cases with more than 10% of positive
tumour cells. Different intensities of TS immunoreactivity were
found in cells within the same tumour. TS positivity was signifi-
cantly higher in females (70% vs 45% respectively; P < 0.05) and
in G1–2 tumours (68% vs 42% respectively; P < 0.04). No associ-
ation was found between intensity (any cut-off level) and any of
the clinical-biological characteristics considered. As previously
stated in the Materials and Methods section, the cut-off value of
0% TS-positive cells was retained for further clinical analyses.
When analysing relationships between p53 and TS staining, a
strong trend was evident for a direct association between TS and
p53 status (positive vs negative) of the individual tumour (overall
agreement: 60%; P > 0.06); conversely, when percentage of
TS- and p53-positive cells in each tumour were considered, a
significant but low degree of correlation was shown (c.c. = 0.216;
P < 0.05) (Figure 2).
With regard to clinical outcome, no statistical association was
demonstrated between p53 positivity (cut-off > 5% of positive
cells) and probability of clinical response to chemotherapy (objec-
tive responses in p53-positive and -negative cases: 20% vs 23%
respectively; hazard risk (HR) 1.2; 95% CI 1.3–0.9; P > 0.5), length
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Figure 2 Percentage of p53-positive cells in relation to percentage of 
TS-positive cells in the primary tumour of 108 advanced colorectal cancer
patients
Figure 1 Immunohistochemical staining of a formalin-fixed paraffin-
embedded human colon carcinoma tissue specimens using antibody TS106TS, p53 as predictive factors in colorectal cancer 563
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of response (6 vs 7 months respectively; P > 0.05 by log-rank test)
and overall survival (11 vs 12 months respectively; P > 0.05 by log-
rank test). This absence of relationships between p53 status and
clinical outcome was also confirmed when different cut-off values
for the p53 status were adopted or subsets of patients with different
clinical-pathological characteristics were compared (colon vs
rectum primary tumour site; recurrent vs initially metastatic
disease; liver vs other metastatic sites).
On the contrary, the probability of clinical response to
chemotherapy was significantly higher in TS-negative with
respect to TS-positive tumours (objective responses: 30% vs 15%
respectively; HR 2.0; 95% CI 3.5–1.2; P < 0.04). Also the mean
TS expression in responder patients was significantly lower than
that of non-responders (mean TS expression: 3% vs 31% respec-
tively; P < 0.05 by t-test) (Figure 3). This association between
clinical response and TS negativity was particularly strong in the
subset of 69 colon cancer patients (45% vs 15% of clinical
responses in TS-negative and -positive colon tumours respec-
tively;  P < 0.02) compared to the 39 rectal cancer patients (33% vs
26% of clinical responses in TS-negative and -positive rectal
tumours respectively; P 5 n.s.). Furthermore, the median time-to-
progression (Figure 4) was the same in TS-negative with respect to
TS-positive cases (6 vs 6 months respectively; P = 0.3) as was also
the overall survival (12 vs 13 months; P > 0.9 by log-rank) (Figure
5). This lack of relationship between TS primary tumour expres-
sion and long-term clinical outcome was also confirmed when
colon and rectal tumours, recurrent and advanced, at first diag-
nosis were separately considered.
The probability of clinical response to chemotherapy in 108
cases according to TS and p53 status is reported in Table 1.
Percentage of clinical response to chemotherapy was 7% for
p53-positive/TS-positive tumours vs 46% for p53-positive/
TS-negative tumours (P < 0.03). Conversely, after stratification
according to TS status, p53 did not individualize subgroups of
patients with a different percentage of clinical responses. The
logistic regression analysis (Table 2) to assess the relative influ-
ence of the number of metastatic sites, location of metastatic site,
and TS primary tumour expression on the probability of a clinical
response to chemotherapy showed that only TS status mantained a
significant association with the clinical response of patients to
chemotherapy (HR 2.91; 95% CI 8.34–1.01; P < 0.05).
Lastly, a Cox multivariate analysis with overall survival as a
dependent variable and the same clinical-biological characteristics
included in the model showed that only the presence of a lesser
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Figure 3 Distribution of percentage of tumour cells positive for TS
immunostaining in a group of 108 advanced colorectal cancer patients with
different clinical response to 5-FU-based chemotherapy
Figure 4 Time-to-progression (TTP) according to TS status of primary
tumour in a series of 108 patients with advanced colorectal cancer (…, TS-
negative, n = 39; —, TS-positive, n = 36)
Table 1 Clinical response to chemotherapy in relation to p53 and TS
tumour status in a series of 108 advanced colorectal cancer patients
Primary tumour
Clinical response (%)
TS/p53 status Responsea No response
p53-negative/TS-negative 10 (24%) 31 (76%)
p53-negative/TS-positive 6 (22%) 21 (78%)
p53-positive/TS-negative 6 (46%)b 7 (54%)
p53-positive/TS-positive 2 (7%)b 25 (93%)
Cut-off for p53 positivity: 5% of immunostained cells. Cut-off for TS positivity:
³ 1% of immunostained cells. aResponse: complete response or partial
response; No response: stable disease or disease progression.
bP < 0.03 by Fisher’s exact test.
Table 2 Logistic regression analysis of clinical response to chemotherapy
in a series of 108 advanced colorectal cancer patients
Variable Hazard risk 95% Confidence P-value
interval
TS statusa 2.91 8.34–1.01 0.05
(negative vs positive)
No. metastases 1.01 1.04–0.98 0.5
(1 vs > 1 site)
Site of 1.14 1.42–0.81 0.8
metastasis
(liver vs other)
a See Table 1 for cut-off value.564 A Paradiso et al
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number of metastatic sites maintained an independent association
(HR 1.89; 95% CI 2.85–1.26; P < 0.03) with overall survival
(Table 3).
DISCUSSION
The p53 tumour suppressor gene, located at chromosomal location
17p13.1, is one of the most commonly alterated genes in human
solid tumours. Alterations consist in a frequent allelic deletion of
the gene and mutations of the remaining allele, generally repre-
sented by point mutations located in exons 4–9 (Greenblatt et al,
1994). With respect to the wild-type protein, which has anti-
oncogenic characteristics and a short half-life of about 15 min, the
mutated p53 protein has a greater stability, a significantly longer
half-life and accumulates within malignant cells thus exerting a
series of negative effects. Its altered properties include the ability
to modify the chemotherapy-induced programmed cell death apop-
tosis (Lowe et al, 1994); in particular, mutational loss of p53
tumour suppressor functions has been associated with a decreased
sensitivity to DNA synthesis blocker drugs such as 5-FU (Mueller
and Eppenberger, 1996). Moreover, the possibility to up-regulate
the expression of the mdr-1, a gene directly involved in pleiotropic
multidrug resistance, has been demonstrated for specific p53
mutations (Chin et al, 1992).
Data available on p53 alterations in human colorectal cancers
demonstrates an approximate frequency of 50% of point mutations
and a percentage of overexpressing tumours varying from 20% to
70% (Smith et al, 1996). Even though controversial results are
reported in the literature, the p53 overexpression is thought to be
prevalently associated with tumour progression and poor patient
prognosis (Greenblatt et al, 1994). On the contrary, studies veri-
fying the capability of p53 status or protein expression to predict
the clinical response of colorectal cancer to chemotherapy are
scarce, limited to small numbers of patients, and are contradictory.
Lenz et al (1998) reported that the p53 status determined by 
cDNA sequencing was associated with response to 5-FU-based
chemotherapy in a series of 36 colorectal cancer patients, while
Bulleco et al did not verify any relationship between p53 expres-
sion and clinical disease response to hepatic artery infusional 
fluorouridine in a series of 50 colorectal cancer patients with 
liver metastases (Bulleco et al, 1996).
In the present study, we update our previous results (Paradiso et
al, 1996) analysing the relationships between p53 primary tumour
expression and clinical outcome in a larger series of advanced
colorectal cancer patients homogeneously treated with a 5-FU-
based chemotherapy regimen. We confirm the absence of associa-
tion between p53 status and clinical response even when different
cut-off values for p53 positivity were considered, and patients with
colon and rectal cancer with recurrent and initially advanced
disease were analysed separately. Contrary to Bulleco et al’s
results (Bulleco et al, 1996), in our experience also the long-term
clinical outcome was not significantly different when plotted
against various p53 levels.
Even though comparative studies on advanced colorectal cancer
series with similar characteristics are not available, some
hypotheses can be forwarded to explain the unexpected absence of
a predictive and prognostic relevance for p53 primary tumour
overexpression in our study. Several mAbs are now available for
the detection of p53 protein reacting at cytoplasmic and nuclear
levels (Bosari and Viale, 1994), recognizing different epitopes
(Smith et al, 1996) with various degrees of resistance to
denaturation (Cook and Milner, 1990); however, their use in clin-
ical series has generated large variations in the p53 characteristics
among the different studies. Our negative results could be specific
for the mAb pAb 180 which reacts with a denaturation-resistant
epitope between amino acids 32 and 79 and recognizes both wild-
type and mutant forms of the p53 protein. Consequently, the
present results might require further studies in which other mAbs
for p53 detection are tested.
Furthermore, the failure to find a significant correlation between
p53 primary tumour expression and clinical outcome could be
based on the sensitivity and specificity of the immunohistochem-
ical assay for p53 expressions compared to molecular techniques.
In fact, strong discrepancies between immunohistochemical and
molecular analysis of p53 within the same sample have been
reported with a generally higher percentage of p53 alterations
resulting with molecular analysis, even if colorectal cancer with
p53 accumulation as detected by immunoassays and not har-
bouring p53 gene mutations has been reported to be quite frequent
(Greenblatt et al, 1994). Interestingly enough, this hypothesis has
been recently verified by Smith et al in a series of 100 colorectal
carcinomas who reported that, while mutations of the p53 gene by
molecular assays provides prognostic information, overexpression
of the p53 protein as detected by mAbs pAb240 and pAb1801 does
not (Smith et al, 1996).
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Figure 5 Overall survival (OS) according to TS status of primary tumour in a
series of 108 patients with advanced colorectal cancer (…, TS-negative, n =
54; —, TS-positive, n = 54)
Table 3 Cox multivariate analysis of overall survival in a series of 108
advanced colorectal cancer patients
Variable Hazard risk 95% Confidence P-value
interval
No. metastases 1.89 2.85–1.26 0.03
1 vs > 1 site
TS status 1.02 1.73–0.60 0.09
negative vs positivea
p53 status 1.12 2.02–0.63 0.6
negative vs positivea
a See Table 1 for cut-off values.TS, p53 as predictive factors in colorectal cancer 565
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It is also possible to hypothesize that the present p53 results,
apparently negative, could be interpreted in the light of activity of
other genes which positively and negatively control the p53-
dependent cell death pathways (Merchant et al, 1996) and also the
p53-mediated G1 arrest (Hermeking and Heick, 1994). From this
point of view, the role of co-expression of Bcl-2 and p53 oncopro-
teins (Bathavdekar et al, 1997; Manne et al, 1997), or that of
proliferating cell nuclear antigen, p21WAF/Cip1 and p53 expres-
sion (Paradiso et al, 1996; Slebos et al, 1996) for prognostic
discrimination of colorectal cancer patients have also been
recently investigated.
TS is the central enzyme in the metabolic pathway responsible
for the final step in the de novo synthesis of thymidilate, a
nucleotide required for the synthesis and maintenance of DNA
integrity. The expression of the TS gene is believed to be cell cycle
associated and high in the S phase (Navalgund et al, 1980), even if
preclinical in vitro studies have demonstrated that high intrinsic
TS levels do not necessarily mean a higher proliferation rate
(Pestalozzi et al, 1995). It has also been suggested that the TS
protein regulates the translational efficiency of its own messenger
RNA (Chu et al, 1991). In human tissues, high TS levels are
generally found in tissues with high cell turnover, such as bone
marrow, spleen, thymus and tumour cells (Spears, 1995). Baseline
TS levels were found by an enzymatic 3H-FdUMP radioligand
binding assay to be higher in primary colon cancers than in liver
metastatic sites (Larsson et al, 1996). Moreover, the expression of
TS has been verified as an important independent predictor of
disease-free survival and overall survival in patients with operable
rectal cancer (Johnston et al, 1994) and early breast cancer
(Pestalozzi et al, 1997).
In addition to the significance of TS in tumour progression and
patient prognosis, considerable effort has been directed to under-
standing the potential clinical predictive role of this enzyme to
determine fluoropyrimidine cytotoxicity. However, available data
regard only limited series of colorectal cancer patients generally
studied by polymerase chain reaction (PCR) and biochemical tech-
niques. Johnston et al (1995) verified a close association between
TS protein and gene expression in response to fluoripyrimidine
and folates in nine colorectal cancers and 12 gastric cancer
patients. Leichman et al (1997), utilizing a PCR technique to
determine TS expression in a series of 46 patients with dissemi-
nated colorectal cancer, confirmed the strong association of TS
level with clinical response of the tumour to 5-FU, and these data
are in agreement with those of Lenz et al in 36 patients (Lenz et al,
1998). Lastly, Peters et al, (1995) and Kornmann et al (1997)
confirmed the association of high total tumour TS catalytic
activity with clinical resistance of the disease in patients treated
with regional chemotherapy.
In these pilot studies, TS quantification was traditionally
performed using biochemical or molecular assays, which have
some major disadvantages, clearly limiting the possibility for their
use in routine clinical activity; the problematic aspects concern the
need for large and freshly frozen tumour tissues, the utilization of
indirect criteria for molecular quantification of the protein level,
the reproducibility of enzymatic assays for evaluation of protein
activity, and the need for a well experienced laboratory team. The
proof of how relevant is the assay utilized for determination of this
enzyme is stressed by the negative-only results reported by
Findlay et al (1997) utilizing a polyclonal antibody to recombinant
TS and a silver-enhanced immunogold staining with image
analysis for TS expression.
Recently, specific mAbs against TS have been synthesized by
recombinant techniques and produced in mice (Johnston et al,
1991). Our experience regards the use of clone TS106 of specific
TS monoclonal antibodies, which has been shown to be valid for
immunological analysis of the protein (Johnston et al, 1991). We
performed islet cell antibody assay for TS analysis on paraffin-
embedded tumour material for which were available the time of
fixation, microwave treatment and time from cutting tumour. Our
results are intriguing in that we effectively verified a significant
association between positive TS expression and clinical resistance
to a fluoropyrimidine-based regimen, demonstrating that TS-posi-
tive tumours have only a 15% probability to respond to therapy
with respect to 30% for TS-negative tumours (P < 0.04). This 
relationship was also confirmed (HR 2.91; 95% CI 8.34–1.01; 
P < 0.05) with a logistic regression analysis with site and number
of metastases included in the model. Therefore, TS seems to be a
statistically relevant marker of clinical response to 5-FU-based
regimens. However, perhaps because of the relatively low number
of patient responders (overall 22% of cases), the median length of
response and overall survival did not differ significantly in TS-
negative with respect to TS-positive tumours. Johnston et al,
analysing in a series of 70 advanced head and neck cancer patients
treated with 5-FU-based neoadjuvant chemotherapy, obtained
similar results with TS expression relevant in predicting clinical
response but not in selecting patients with different long-term clin-
ical outcome (Johnston et al, 1997). On the contrary, Lenz et al
utilizing reverse transcription PCR (RT-PCR) assay for TS quanti-
tation in 36 colorectal cancers, reported that TS expression signif-
icantly predicts 5-FU tumour response but also a different overall
survival (Lenz et al, 1998).
Our last comment concerns the relationship between p53 and
TS. By verifying that mean TS levels of tumours with wild-type
p53 were significantly lower compared to tumours with mutated
p53, Lenz et al hypothesized a regulatory bond between p53 and
TS genes (Lenz et al, 1998). Recently, Lee et al confirmed this
possibility demonstrating that the wild-type p53 protein is able to
inhibit the activity of mouse TS promoter activity (Lee et al,
1997). Our data can be inserted in this scenario as we found
different TS characteristics for tumours with different p53 expres-
sion; in fact, the percentage of TS-negative tumours was signifi-
cantly lower in p53-positive than in p53-negative tumours (40% vs
67% respectively; P < 0.05). Furthermore, the association between
TS status with clinical response significantly differs only in p53-
positive (46% vs 8% respectively in TS-negative and -positive
tumours) and not in p53-negative tumors (22% vs 24% respec-
tively). In conclusion, taking into account the preliminary data of
Lenz et al who obtained the same clinical results utilizing cDNA
sequencing for analysis of p53 status and RT-PCR for TS quantita-
tion (Lenz et al, 1998), we can confirm that the role of TS in the
modulation of clinical response to fluoropyrimidines seems to be
different in tumours with a different p53 status. This is one of the
first clinical results directly relating the role of a key enzyme to the
cytotoxic effect of a specific drug, such as that of TS for 5-FU,
with alterations of p53, a gene able to conduct the tumour cell to
apoptotic death and/or G1 arrest.
Our results have been obtained with a relatively easy and
feasible technique such as the immunohistochemical assay, which566 A Paradiso et al
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permits the evaluation of large retrospective series and is of poten-
tial routine application in prospective trials. However, we think
that further studies on large retrospective series are needed before
the application of p53 and TS tumour expression as predictive
factors in prospective clinical trials for patients with advanced
colorectal cancer.
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